Merck & Co., Inc. Hits New 52-Week High at $135.02

Merck & Co., Inc. has reached a significant milestone by hitting a new 52-week high of USD 135.02 on July 28, 2026. This achievement underscores the company's strong position within the Pharmaceuticals & Biotechnology industry, where it operates as a large-cap entity with a market capitalization of USD 421,597 million. In the past year, Merck's stock performance has shown a modest increase of 0.25%, particularly when compared to the S&P 500's performance of 16.26%. The company's price-to-earnings (P/E) ratio stands at 19.00, indicating a competitive valuation within its sector. Additionally, Merck boasts a solid dividend yield of 4.00%, appealing to income-focused investors. Financially, Merck maintains a debt-to-equity ratio of 0.66, reflecting a balanced approach to leveraging, while its return on equity is an impressive 42.82%. The stock's price-to-book ratio is recorded at 8.01, further illustrating its valuation metrics. Overall, Merck & Co., Inc.'s recent performance and financial indicators highlight its robust standing in the market.